All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists

Loreto Carmona, Miguel Ángel Descalzo, Eva Perez-Pampin, Dolores Ruiz-Montesinos, Alba Erra, Tatiana Cobo, Juan J Gómez-Reino and on behalf of the BIOBADASER and EMECAR Groups


Updated information and services can be found at:
http://ard.bmj.com/cgi/content/full/66/7/880

These include:

References
This article cites 48 articles, 14 of which can be accessed free at:
http://ard.bmj.com/cgi/content/full/66/7/880#BIBL

Open Access
This article is free to access

Rapid responses
You can respond to this article at:
http://ard.bmj.com/cgi/eletter-submit/66/7/880

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Notes

To order reprints of this article go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to Annals of the Rheumatic Diseases go to:
http://journals.bmj.com/subscriptions/
EXTENDED REPORT

All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists

Loreto Carmona, Miguel Ángel Descalzo, Eva Perez-Pampin, Dolores Ruiz-Montesinos, Alba Erra, Tatiana Cobo, Juan J Gómez-Reino, on behalf of the BIOBADASER and EMECAR Groups*

See end of article for authors’ affiliations

Correspondence to: Dr JJ Gómez-Reino, Rheumatology Service, Department of Medicine, Hospital Clínicas Universitario, A Choupana s/n, 15706 Santiago, Spain; juan.gomez-reino.carnota@sergas.es

Accepted 19 February 2007
Published Online First 23 February 2007

Background: Mortality is increased in rheumatoid arthritis (RA), mainly because of cardiovascular (CV) events, cancer and infections. Recent data suggest that treatment with tumour necrosis factor (TNF) antagonists may affect this trend.

Objective: To assess whether treatment with TNF antagonists is associated with reduction in CV events, cancer and infection rates, and mortality in patients with RA treated and not treated with TNF antagonists.

Methods: BIOBADASER is a registry for active long-term follow-up of safety of biological treatments in patients with RA. It includes 4459 patients with RA treated with TNF antagonists. EMECAR is an external RA cohort (n = 789) established to define the characteristics of the disease in Spain and to assess comorbidity. The incidence density (ischaemic heart disease) of CV events, cancer and infections was estimated and compared. The standardised mortality ratio was compared with the rate in the general population. A propensity score was used to match cohorts by the probability of being treated.

Results: Rates of CV and cancer events are significantly higher in EMECAR than in BIOBADASER (RR 5–7 for different CV events, and RR 2.9 for cancer), whereas the rate of serious infections is significantly higher in BIOBADASER (RR 1.6). Mortality ratio of BIOBADASER by EMECAR is 0.32 (0.20–0.53) for all causes of death, 0.58 (0.24–1.41) for CV events, 0.52 (0.21–1.29) for infection and 0.36 (0.10–1.30) for cancer-related deaths.

Conclusion: Morbidity, other than infection, and mortality are not higher than expected in patients with RA treated with TNF antagonists.

In most studies, mortality in rheumatoid arthritis (RA) is higher than expected.1–3 This excess of mortality pertains largely to cardiovascular (CV) diseases as in the general population, yet in RA4–7 traditional CV risk factors do not satisfactorily account for the surplus of deaths.8–9 In fact, high levels of inflammation reflected by activity scores or extra-articular disease are more robust predictors of premature CV mortality than high cholesterol level or high blood pressure.10–14 In RA15 and in arteriosclerosis,16 chronic inflammation plays a role as an atherogenic factor.17 Early and aggressive control of the inflammation results in improved survival.18–20 Additional conditions contributing to the excess of mortality in RA are infections and cancer. Both infections and cancer are related to the extent and severity of arthritis.21 22 23 Interestingly, patients with RA with more severe disease are currently treated with TNF antagonists, which are associated with serious infections and with malignancies,24 and deterioration of heart function and heart failure.25–27

Patients and Methods

The present study is based on the comparison of two nationwide cohorts, one available from a drug registry, BIOBADASER (2001–6), and the other, EMECAR (1999–2005), from a cohort of patients with RA. Both BIOBADASER and EMECAR cohort studies were approved by their corresponding ethical committees.

The BIOBADASER cohort

A description of BIOBADASER has been published elsewhere.28–30 BIOBADASER is a drug safety registry launched in February 2000 for active long-term follow-up of patients with RA treated with biological response modifiers. The registry has generated an open cohort of patients in 100 participating centres of patients starting treatment for the first time with a TNF antagonist and followed thereafter. The registry protocol and materials were approved by the Spanish Medicines Agency, and data regarding patients were gathered according to the present official regulations on data protection. Any change in the treatment as well as relevant adverse events (AEs) occurring during follow-up are registered.

Data collected systematically include gender, date of birth, diagnosis and date of diagnosis of the patients, treatment type and dates of initiation and of discontinuation of the treatment. When a patient has a relevant AE, additional data are registered, including the date of occurrence, type and classification of AE according to the World Health Organization Dictionary of adverse drug reactions, outcome of AE, concomitant treatment and comorbidity. AEs are reported as they occur. Once a year, all participants are requested to update the

Abbreviations: AE, adverse event; CV, cardiovascular; DAS, disease activity score; RA, rheumatoid arthritis; SMR, standardised mortality ratio; TNF, tumour necrosis factor

www.annrheumdis.com
patients registered in their centre, prior to downloading the database for analysis. Furthermore, completeness and agreement of data with patients' charts are assessed in situ by yearly audits of 10% of the patients registered in BIOBADASER, chosen randomly. A total of 665 clinical records from 82 centres were reviewed in the audit before the present analysis; 14% of entries had errors in notifications. All inaccuracies were corrected accordingly, yielding an expected error of 11%. Patients coming from centres where the audits revealed incompleteness of the data (n = 12) were censored at the time of the last reliable information. To improve comparability with the EMECAR cohort, only data from patients with RA who had been in the registry before January 2002 were analysed (n = 789), thus ensuring a similar observation time of 5 years with EMECAR.

The EMECAR cohort
The EMECAR cohort has also been described previously.31–33 It comprises 789 patients in whom clinical expression, disease activity and progression of the disease, and comorbidity have been prospectively collected in yearly visits for 5 years according to a structured protocol. EMECAR strengths are that (1) it represents the Spanish population with RA, as it was assembled by random sampling from clinical databases of 34 rheumatology units; (2) it was started in 1999, before any biological treatment was available in Spain; and (3) it was assembled specifically to assess comorbidity and mortality in RA. For the present study, all data on patients in EMECAR who were treated during the observational period with TNF antagonists were censored at the time of the first dose. The numbers of patients starting treatment with TNF antagonists in EMECAR at 1, 3 and 5 years of follow-up were 11 (1.4%), 63 (10.5%) and 78 (16.8%), respectively.

The BIOBADASER subsample
As neither comorbidity nor clinical data were collected at baseline in BIOBADASER, four participating centres were asked to report these specific data. The centres were selected on the following bases: (a) being from four different regions (north, south, east and central Spain); (b) having contributed information on at least 100 patients in the registry; and (c) having their patients in prospective clinical cohorts, thus ensuring good-quality data. In total, these four centres contributed information on 437 patients with RA (67 in the registry before January 2002). Figure 1 shows the flow of selection of patients to make both cohorts comparable.

Definitions of risk factors and cause of death
The working definitions of CV risk factors in the four BIOBADASER centres and EMECAR were similar: (1) Hypercholesterolaemia was defined as a cholesterol level >240 mg/dl (6.5 mmol/l) in two separated occasions, or need for cholesterol-lowering medication; (2) Hypertension was defined as a systolic blood pressure >140 mm Hg, or as a diastolic blood pressure >90 mm Hg, or the need for antihypertensive treatment; (3) Diabetes was defined by the National Institute of Health National Diabetes Data Group criteria of 1979 as fast glucose level >7.8 mmol/l (140 mg/dl) in two separate occasions, or a glucose level >11.1 mmol/l (200 mg/dl) 2 h after taking 75 g of oral glucose in two separate occasions; (4) Obesity was defined as a body mass index >30 kg/m². “Smoking habit” had a broader definition in EMECAR as “ever smoking”, whereas in the four BIOBADASER centres a smoking habit was defined as smoking any amount of cigarettes per day at the time of the interview. Date of death and cause of death were obtained from charts, patients’ families and regional death registries.

Statistical methods
Student’s t and χ² tests were used to compare differences in baseline variables in BIOBADASER and EMECAR cohorts. Incidence rates per 100 000 patient-years of CV events, infections and cancer, with 95% CIs, were estimated in the two cohorts. Time of observation for the patients comprised the period from the baseline date until occurrence of any of the following: death from any cause; last reliable audit of a centre (only in BIOBADASER) loss of follow-up, beginning of any biological treatment (only in EMECAR), or end of follow-up.
Standardised mortality ratios (SMRs) with 95% CIs were calculated as the ratio of observed by expected deaths by the indirect method, using the 2002 population mortality data of all-cause and cause-specific deaths. Data on Spanish mortality stratified by age and gender were obtained from the National Institute of Statistics (Instituto Nacional de Estadística). Mortality ratios and 95% CIs between both cohorts were also calculated, as an effect measure.

Because of a small but statistically significant difference in baseline disease severity between BIOBADASER and EMECAR cohorts, the probability of being treated with biologicals (propensity score) was used to match cases from the BIOBADASER subsample with controls from the single nearest-neighbour in EMECAR. The propensity score included baseline age, DAS28, disease duration and gender, and it was calculated with STATA-specific commands. The resulting data file of cases and controls was used to compare the effect of exposure to TNF antagonists on mortality, by means of the rate ratio. All analyses were performed by using the statistical program STATA V.9.2.

RESULTS

The selected cohorts with RA provided information on 2868 patient-years treated with TNF antagonists (BIOBADASER) and 2433 patient-years (EMECAR) not treated with TNF antagonists. Table 1 shows baseline characteristics of the patients in the two cohorts as well as in the two subsamples; one from the four BIOBADASER centres with prospective cohorts and the other from the controls in the EMECAR cohort matched by the propensity score.

Patients in the EMECAR cohort showed a CV profile similar to the patients in BIOBADASER, except for EMECAR patients being 2 years older and having a higher prevalence of smoking, perhaps because of a broader definition of smoking.

Table 2 shows the incidence of CV events, infections and cancer in the cohorts, with 95% CIs, in BIOBADASER and in EMECAR. Rates of all CV events and of cancer are significantly higher in EMECAR than in BIOBADASER, whereas the rate of serious infections is higher in BIOBADASER. Given the difference in age

| Table 1 | Baseline characteristics of the patients included in the two cohorts as well as in the two subsamples: subsample 1 includes patients from four BIOBADASER centres, subsample 2 was drawn randomly from EMECAR to match with the BIOBADASER subsample (see Methods: propensity score) |
|------------------------|-----------------|-----------------|-----------------|
| Descriptor             | BIOBADASER (n = 789) | Subsample 1 (n = 67) | EMECAR (n = 789) | Subsample 2 (n = 67) |
| Age (years), mean (SD) | 59 (13)          | 53 (13)          | 61 (13)*         | 52 (11)          |
| Women, n (%)           | 621 (79)         | 54 (81)          | 568 (72)*        | 56 (84)          |
| Disease Activity Score, mean (SD) | 6.1 (1.2) | 4.2 (1.4)* | 5.9 (1.1) |
| Treated with methotrexate, n (%) | 20 (71) | 546 (70) | 62 (93) |
| Hypercholesterolaemia, n (%) | 14 (30) | 241 (31) | 15 (22) |
| Diabetes, n (%)        | 3 (7)            | 70 (9)           | 6 (9)            |                  |
| Hypertension, n (%)    | 12 (26)          | 286 (37)         | 19 (28)          |                  |
| Smoking habit, n (%)   | 4 (9)            | 239 (30)*        | 21 (31)*         |                  |
| Obesity, n (%)         | 10 (24)          | 160 (21)         | 13 (19)          |                  |

*p < 0.01 between EMECAR and BIOBADASER.
*tp < 0.01 between EMECAR and BIOBADASER subsamples.
*tp < 0.01 between EMECAR and BIOBADASER subsamples.

Table 2 | Incidence of cardiovascular events, infections and cancer per 100 000 patient-years, with 95% CIs, in the two cohorts |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Descriptor</td>
<td>BIOBADASER Cases</td>
<td>Patient-years</td>
<td>Incidence rate</td>
</tr>
<tr>
<td>Ischaemic heart disease</td>
<td>4</td>
<td>2855</td>
<td>140 (53 to 373)</td>
</tr>
<tr>
<td>Younger than 60</td>
<td>1</td>
<td>1548</td>
<td>65 (9 to 459)</td>
</tr>
<tr>
<td>60 or older</td>
<td>3</td>
<td>1307</td>
<td>229 (74 to 712)</td>
</tr>
<tr>
<td>Cardiac failure</td>
<td>5</td>
<td>2860</td>
<td>175 (73 to 420)</td>
</tr>
<tr>
<td>&lt;60 years</td>
<td>0</td>
<td>1552</td>
<td>0</td>
</tr>
<tr>
<td>60 or older</td>
<td>5</td>
<td>1308</td>
<td>382 (159 to 918)</td>
</tr>
<tr>
<td>Stroke</td>
<td>3</td>
<td>2858</td>
<td>105 (34 to 326)</td>
</tr>
<tr>
<td>&lt;60 years</td>
<td>1</td>
<td>1552</td>
<td>64 (9 to 457)</td>
</tr>
<tr>
<td>60 or older</td>
<td>2</td>
<td>1306</td>
<td>153 (38 to 612)</td>
</tr>
<tr>
<td>Infections</td>
<td>114</td>
<td>2644</td>
<td>4312 (3589 to 5181)</td>
</tr>
<tr>
<td>&lt;60 years</td>
<td>41</td>
<td>1452</td>
<td>2823 (2079 to 3834)</td>
</tr>
<tr>
<td>&lt;60 years</td>
<td>73</td>
<td>1192</td>
<td>6126 (4870 to 7706)</td>
</tr>
<tr>
<td>Cancer</td>
<td>11</td>
<td>2879</td>
<td>382 (212 to 690)</td>
</tr>
<tr>
<td>&lt;60 years</td>
<td>7</td>
<td>1318</td>
<td>256 (96 to 683)</td>
</tr>
<tr>
<td>60 or older</td>
<td>4</td>
<td>1561</td>
<td>531 (253 to 1115)</td>
</tr>
</tbody>
</table>

The rate in patients >60 or <60 years is also shown.
in the comparison cohort, incidence rates were stratified by age, 60 years being the strata. Despite the small size of the strata, patients aged >60 years showed a significant difference rate of ischaemic heart disease and cardiac failure in both cohorts.

Mortality

A total of 75 patients in the EMECAR cohort died (32 men and 43 women), but only 50 were expected to die. The main causes of death were CV disease (n = 17; 23%), infection (n = 14; 19%) and cancer (n = 13; 17%). The cause of death was unknown in 14 (19%) patients. In the BIOBADASER cohort, 20 patients died in the same period (5 men and 15 women), but 38 were expected to die. The main causes of death, known in all cases, were infections (n = 7; 35%), CV disease (n = 7; 35%) and cancer (n = 3; 15%). Table 3 shows SMRs in BIOBADASER and EMECAR, by cause of death and sex, and mortality ratios, adjusted by age and sex, between both cohorts (BIOBADASER/EMECAR).

When subsamples matched by the propensity score were analysed, SMR for all causes changed in BIOBADASER from a 50% to a 40% reduction and SMR 0.648 (0.079 to 2.342); SMR of men 0 (0 to 6.743), SMR of women 0.788 (0.096 to 2.847). In EMECAR, the change was even more noticeable, with SMR 3.052 (0.832 to 7.814); SMR of men 1.633 (0.041 to 9.100), SMR of women 4.296 (0.886 to 12.554). Given the small sample size, only death from all causes was analysed. The MRR of the BIOBADASER subsample by the EMECAR subsample was 0.324 (0.06 to 1.77), 0.224 (0.04 to 1.31) adjusted by age, and 0.191 (0.03 to 1.30) adjusted by age and gender, reaching significance (p = 0.10).

**DISCUSSION**

In the present study, we have investigated the impact of TNF antagonists on the survival of patients with RA. Our study shows that mortality from non-infectious causes is decreased in this selected population as compared with patients with RA not exposed to TNF antagonists. Furthermore, reduction in mortality from cardiac causes seems to be the major reason for this decline. However, a significant increase in the rate of relevant infections in patients treated with TNF antagonists occurs.

There are some limitations to our study. The control cohort was not a true internal cohort. However, the EMECAR cohort was assembled from 90% of hospitals actively including patients in the BIOBADASER registry, and therefore patients in both BIOBADASER and EMECAR cohorts should have received similar care. Patients in EMECAR have milder activity (baseline DAS) and this may be the reason why only few patients received TNF antagonists when available. Nevertheless, EMECAR may replicate the improvement in survival associated with the recent awareness that a more aggressive and early control of disease activity should be the standard of treatment in RA. Moreover, BIOBADASER patients were on average 2 years younger than EMECAR patients. This may have an impact on CV morbidity and mortality, balanced nonetheless by the larger number of women in EMECAR with a lower mortality. Of note, comorbidities in EMECAR did not diverge substantially from BIOBADASER except for hypertension and smoking habits, both related perhaps to a more active search in EMECAR (designed specifically to study comorbidity in RA) than to a true high prevalence. Activity, and not other factors, was the major drive for the use of TNF antagonists in BIOBADASER. Thus, a bias to the use of TNF antagonists in patients with fewer comorbidities or absence of comorbidities associated with higher mortality does not seem to be the explanation for the differences in mortality in our study. Nevertheless, observational studies of exposed and unexposed patients may differ systematically with regard to variables related to exposure or outcome. However, adjustment by matching exposed and unexposed patients with regard to known conditional exposure prognostic variables (propensity score) as in our work leads to unbiased estimates and tests of exposure effect. Another potential bias is the incompleteness of the data in BIOBADASER. If we assume 11% error, as revealed by repeated audits, the mortality would still be lower than expected. In the worst scenario, the number of deaths would be 22 instead of 20, the number of patient-years of follow-up 2868 instead of 2550, and the MRR of BIOBADASER by EMECAR 0.280 (0.166 to 0.455).

As the doctors involved in the care of EMECAR patients were largely the same as those treating BIOBADASER patients, the reporting of causes of death should not have differed significantly. This issue may be relevant in the case of deaths from cancer, attributed, on occasions to infection or CV events rather than to the primary condition especially in elderly patients with comorbidities. Still, the cause of death in EMECAR was unknown in a number of cases. If all these deaths are attributed to a CV cause as is commonly the case, the difference with BIOBADASER would be even larger. On the contrary, attributing the unknown causes of death to infection would probably be more realistic, and the rate of deaths from infection in EMECAR and BIOBADASER would be similar.

**Table 3** Standardised mortality ratios and 95% CIs of patients with rheumatoid arthritis treated or not with tumour necrosis factor antagonists with respect to the expected rate in the general population of Spain

<table>
<thead>
<tr>
<th></th>
<th>BIOBADASER</th>
<th>EMECAR</th>
<th>Mortality rate ratios*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All causes</strong></td>
<td>0.516 (0.315 to 0.797)</td>
<td>1.493 (1.174 to 1.872)</td>
<td>0.32 (0.20 to 0.53)†</td>
</tr>
<tr>
<td>Men</td>
<td>0.469 (0.152 to 1.095)</td>
<td>1.548 (1.059 to 2.185)</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>0.534 (0.299 to 0.881)</td>
<td>1.455 (1.053 to 1.960)</td>
<td></td>
</tr>
<tr>
<td><strong>Cardiovascular</strong></td>
<td>0.510 (0.205 to 1.050)</td>
<td>0.937 (0.546 to 1.450)</td>
<td>0.58 (0.24 to 1.41)</td>
</tr>
<tr>
<td>Men</td>
<td>1.281 (0.349 to 3.281)</td>
<td>1.227 (0.530 to 2.417)</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>0.283 (0.058 to 0.826)</td>
<td>0.774 (0.354 to 1.470)</td>
<td></td>
</tr>
<tr>
<td><strong>Infectious</strong></td>
<td>11.294 (4.541 to 23.270)</td>
<td>18.676 (10.210 to 31.335)</td>
<td>0.52 (0.21 to 1.29)</td>
</tr>
<tr>
<td>Men</td>
<td>5.589 (0.142 to 31.141)</td>
<td>10.069 (2.077 to 29.427)</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>13.609 (4.994 to 29.622)</td>
<td>24.352 (12.156 to 43.572)</td>
<td></td>
</tr>
<tr>
<td><strong>Cancer</strong></td>
<td>0.284 (0.059 to 0.831)</td>
<td>0.988 (0.526 to 1.689)</td>
<td>0.36 (0.10 to 1.30)</td>
</tr>
<tr>
<td>Men</td>
<td>0.000 (0.000 to 0.952)</td>
<td>1.660 (0.829 to 2.970)</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>0.450 (0.093 to 1.314)</td>
<td>0.306 (0.037 to 1.106)</td>
<td></td>
</tr>
</tbody>
</table>

Mortality ratios and 95% CIs (BIOBADASER/EMECAR). Adjusted by age and sex. *Adjusted by age and sex. **Adjusted by age and sex. 1p<0.001.

www.annrheumdis.com
Basic and clinical studies have demonstrated that CV damage in RA may be, in part, due to a deleterious effect of TNF on the endothelium.42 43 Present data show that TNF blockade is able to partially normalise endothelial function in patients with RA.44 45 Furthermore, an impact of TNF antagonists on the CV-related mortality has been suggested by preliminary reports46 47 and supported by the finding of a large number of TNF-expressing monocytes in fresh thrombi from patients with myocardial infarction.48 It could be proposed that patients treated with TNF antagonists could have undergone closer follow-up and control of comorbidities. This may be one of the reasons why death from cancer, CV disease and infection was lower in BIOBADASER than in EMECAR, despite a higher rate of relevant infections in BIOBADASER. The low rate of death from cancer has been published previously.43 By contrast, recent meta-analysis of randomised controlled trials showed a clear increase in the risk of death from cancer in patients with RA treated with TNF antagonists. This issue needs further investigation.

Finally, comparison of TNF antagonists would have been interesting. Unfortunately, our samples were too small for this purpose. Besides, the observation time for all three biologicals was different as they became available at different times, which may also have an impact on mortality.

In conclusion, mortality in patients with RA who have been treated with TNF antagonists is not different from the general population of similar age and gender. Furthermore, mortality in this cohort of patients is clearly reduced compared with patients with RA not treated with TNF antagonists, owing to the reduction of deaths from non-infectious causes.

ACKNOWLEDGEMENTS

The BIOBADASER registry is supported by the Spanish Society of Rheumatology and by the Spanish Medicines and Medical Devices Agency. Started in year 2006, BIOBADASER is also supported by grants of similar quantity from Schering-Plough, Wyeth, Abbott, Biogen Immunology, Roche Farma and Bristol-Myers Squibb, Spain. The EMECAR cohort was supported by the Spanish Society of Rheumatology and by Aventis. We are indebted to Raquel Ruiz for her secretarial work and diligence with all her commitments in the studies.

Authors’ affiliations

Loreto Carmona, Miguel Ángel Descalzo, Research Unit, Spanish Foundation of Rheumatology, Madrid, Spain
Eva Perez-Pampin, Juan J Gómez-Reino, Rheumatology Service, Department of Medicine, Hospital Clinico Universitario, Medical School, Universidad de Santiago de Compostela, Santiago de Compostela, Spain
Dolores Ruiz-Montesinos, Rheumatology Service, Hospital Virgen Macarena, Sevilla, Spain
Alba Erra, Rheumatology Service, Hospital Vall d’Hebron, Barcelona, Spain
Tatiana Cobo, Rheumatology Service, Hospital La Paz, Madrid, Spain

Competing interests: JGCR is on the Advisory Boards of Wyeth and Schering Plough, and has received lecture fees from Abbott, Wyeth, and Schering Plough.

*Author list appears in the appendix.

REFERENCES

34 Leuen I, Stanesci B, eds. PSMATCH2: State module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing, 2003.

www.annrheumdis.com
Mortality and TNF antagonists


APPENDIX: BIOBADASER AND EMECAR STUDY GROUPS (IN ALPHABETICAL ORDER)